Esperion Therapeutics Inc (ESPR)
1.99
-0.14
(-6.57%)
USD |
NASDAQ |
Apr 25, 16:00
2.01
+0.02
(+1.01%)
After-Hours: 20:00
Esperion Therapeutics Net Income (Quarterly): -56.34M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -56.34M |
| September 30, 2023 | -41.25M |
| June 30, 2023 | -49.94M |
| March 31, 2023 | -61.72M |
| December 31, 2022 | -55.49M |
| September 30, 2022 | -55.12M |
| June 30, 2022 | -66.32M |
| March 31, 2022 | -56.73M |
| December 31, 2021 | -65.12M |
| September 30, 2021 | -69.39M |
| June 30, 2021 | -43.67M |
| March 31, 2021 | -90.94M |
| December 31, 2020 | -104.48M |
| September 30, 2020 | -85.44M |
| June 30, 2020 | 124.61M |
| March 31, 2020 | -78.25M |
| December 31, 2019 | -61.95M |
| September 30, 2019 | -68.38M |
| June 30, 2019 | -54.22M |
| March 31, 2019 | 87.38M |
| December 31, 2018 | -60.04M |
| September 30, 2018 | -49.91M |
| June 30, 2018 | -45.73M |
| March 31, 2018 | -46.13M |
| Date | Value |
|---|---|
| December 31, 2017 | -37.89M |
| September 30, 2017 | -45.22M |
| June 30, 2017 | -43.34M |
| March 31, 2017 | -40.54M |
| December 31, 2016 | -28.96M |
| September 30, 2016 | -17.40M |
| June 30, 2016 | -14.04M |
| March 31, 2016 | -14.58M |
| December 31, 2015 | -13.12M |
| September 30, 2015 | -12.80M |
| June 30, 2015 | -12.40M |
| March 31, 2015 | -11.47M |
| December 31, 2014 | -9.457M |
| September 30, 2014 | -9.806M |
| June 30, 2014 | -9.238M |
| March 31, 2014 | -7.874M |
| December 31, 2013 | -9.689M |
| September 30, 2013 | -5.238M |
| June 30, 2013 | -6.921M |
| March 31, 2013 | -4.239M |
| December 31, 2012 | -2.776M |
| September 30, 2012 | -3.351M |
| June 30, 2012 | -3.166M |
| March 31, 2012 | -2.449M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-104.48M
Minimum
Dec 2020
124.61M
Maximum
Jun 2020
-54.74M
Average
-61.72M
Median
Mar 2023
Net Income (Quarterly) Benchmarks
| United Therapeutics Corp | 217.10M |
| Masimo Corp | 33.90M |
| Heron Therapeutics Inc | -10.72M |
| Aldeyra Therapeutics Inc | -4.753M |
| Ocugen Inc | -9.493M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 32.25M |
| Total Expenses (Quarterly) | 74.62M |
| EPS Diluted (Quarterly) | -0.50 |
| Enterprise Value | 547.60M |
| Gross Profit Margin (Quarterly) | 64.49% |
| Profit Margin (Quarterly) | -174.7% |
| Earnings Yield | -106.5% |
| Normalized Earnings Yield | -106.53 |